Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTX-DED for the Treatment of Dry Eye Disease Symptoms
NCT05814757Phase 2Completed
- Sponsor
- Ocular Therapeutix
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Hydrogel Systems, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OTX-DED in dry eye disease (DED) (3 arms), sponsored by Ocular Therapeutix. Primary endpoint: Severity of Eye Dryness Score (Visual Analogue Scale) at Day 15. Started May 2023; status: completed.
02
Drugs
OTX-DED
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05814757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814757.